Previous close | 234.80 |
Open | 235.10 |
Bid | 237.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 234.00 - 237.80 |
52-week range | 212.90 - 293.55 |
Volume | |
Avg. volume | 1,492,717 |
Market cap | 191.277B |
Beta (5Y monthly) | 0.16 |
PE ratio (TTM) | 16.56 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 9.60 (4.05%) |
Ex-dividend date | 14 Mar 2024 |
1y target est | N/A |
Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen are included in this Analyst Blog.
Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this space.
Reddit content is coming to OpenAI’s chatbot, Roche’s weight-loss drug impresses analysts in early-stage trials, and other news to start your day.